Alvotech Wins FDA Nod for 2nd Simlandi Manufacturing Suite
Alvotech has received FDA approval for a second manufacturing suite at its Reykjavik facility for the Humira biosimilar Simlandi (adalimumab-ryvk), effectively doubling the drug substance capacity for the US market. This approval addresses previous regulatory concerns and enhances operational flexibility, allowing Simlandi's drug substance to be produced in either of two suites. The decision also bodes well for other Alvotech biosimilar applications tied to the Reykjavik site, although each remains subject to independent FDA review.
Moderna Inc Stock (MRNA) Moved Up by 5.71% on Oct 5: What Investors Need To Know
Moderna Inc. (MRNA) stock rose by 5.71% due to its upcoming inclusion in the Nasdaq-100 Index, the return of a seasoned executive as COO, and continued optimism surrounding its Merck-partnered oncology pipeline. Despite recent valuation downgrades and operational losses, investor focus remains on the long-term potential of messenger RNA applications in oncology. Key drivers moving forward include index rebalancing, clinical data from medical presentations, and execution under the new management team.
Twist Bioscience Stock Rallies As AI Drug Deals Drive Targets Higher
Twist Bioscience (TWST) stock has rallied over 7% following a high-profile data and antibody services agreement with Eli Lilly's AI/ML drug discovery platform, TuneLab. This deal positions Twist Bioscience as a "picks-and-shovels" supplier for AI drug discovery, leading Wall Street analysts like Leerink and Guggenheim to significantly raise their price targets for TWST, despite the company still reporting net losses. The company aims for adjusted EBITDA breakeven by Q4 FY26, driven by strong revenue growth and a high gross margin.
Twist Bioscience stock hits 52-week high at 200.49 USD
Twist Bioscience (TWST) stock reached a new 52-week high of $200.49, currently trading at $200.95 with a market capitalization of $12.28 billion. The company has seen a 495% year-to-date surge and a 507% increase over the past year, although InvestingPro data suggests the stock is overvalued. Recent developments include a partnership with Lilly TuneLab for antibody characterization and a prospectus supplement for share resale, alongside mixed analyst ratings and short-seller skepticism regarding AI claims.
Eli Lilly reports Foundayo data and Berenberg rates Eli Lilly stock Buy
Eli Lilly announced new Foundayo data showing cardiovascular safety, sustained A1C reduction, and weight loss, expanding its pipeline beyond Mounjaro and Zepbound. Berenberg rated Eli Lilly stock a "Buy" with a USD 1,400.00 target. The company reported strong Q2 2026 revenues of USD 22.97 billion, a 47.70% year-over-year increase, and raised its full-year 2026 revenue guidance to USD 85.0 billion to USD 87.0 billion.
Eli Lilly and Co. stock pre-market at EUR 1,021.50: plus 0.48 percent
Eli Lilly and Co. stock saw a pre-market increase of 0.48 percent to EUR 1,021.50 on October 5, 2026. This rise follows the U.S. FDA's approval of an expanded indication for Lilly's drug Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The approval was based on positive results from the Phase 3 BRUIN CLL-313 study, which showed improved progression-free survival and overall response rates for pirtobrutinib.
Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech
This article compares two healthcare exchange-traded funds (ETFs): Fidelity's FHLC, which offers broad, low-cost exposure to the entire healthcare sector, and State Street's XBI, which focuses more narrowly on biotechnology. FHLC is presented as a more conservative option with a lower expense ratio and higher dividend yield, while XBI offers higher potential returns but also greater volatility due to its biotech focus. The choice between the two depends on an investor's risk tolerance and desired exposure to the healthcare industry.
Pfizer Inc. Stock Grades | PFE
This article provides detailed stock information for Pfizer Inc. (PFE), including its current stock price, market performance metrics, analyst ratings, and key financial data. It also outlines the company's business activities as a global biopharmaceutical company and compares its performance with peer companies in the industry.
Lilly and Novo share GLP-1 longevity data
Novo Nordisk and Eli Lilly presented early, unpublished data at ARDD 2026 regarding the longevity potential of GLP-1 receptor agonists. Novo's data suggested semaglutide could lead to 1.9 years of additional life expectancy and showed reduced biological aging, while Lilly's epigenetic sub-study on tirzepatide indicated a slower pace of biological aging. Both companies acknowledged the preliminary nature of their findings but are building an evidence base that GLP-1s could function as longevity drugs.
Eli Lilly expands Jaypirca use as Eli Lilly stock trades EUR 1016.60 flat
Eli Lilly's stock traded flat at EUR 1016.60 in weekend trading on October 4, 2026, matching its closing price from October 2, 2026. This stability follows the U.S. FDA's approval of an expanded indication for Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion. The approval was based on positive results from the Phase 3 BRUIN CLL-313 trial, showing significantly improved progression-free survival with pirtobrutinib.
Eli Lilly stock falls 0.61 percent as pipeline data arrive
Eli Lilly and Co. stock closed down 0.61 percent at USD 1,142.85 on October 2, 2026, despite positive pipeline data related to its obesity, diabetes, and oncology franchises. The company reported strong Q2 2026 revenue of USD 22.97 billion, up 47.7 percent year over year, and beat EPS estimates. Analysts maintain a "Moderate Buy" consensus with an average target price 14.80 percent above the current trading price, ahead of its Q3 2026 earnings report on October 29.
Eli Lilly & Co (LLY) Gets a Buy from RBC Capital
RBC Capital analyst Trung Huynh maintained a Buy rating on Eli Lilly & Co (LLY) with a price target of $1,500.00, following the company's strong Q2 earnings report. Another firm, TD Cowen, also reiterated a Buy rating with a $1,250.00 price target. The analyst consensus for Eli Lilly & Co is a Strong Buy, with a collective price target suggesting an 18.64% upside.
Eli Lilly launches access initiative. Eli Lilly stock costs EUR 1,016.60
Eli Lilly has launched its "Change the Course Commitment" initiative, aiming to achieve parity in patient treatment with its diabetes and obesity medicines in resource-limited and high-income countries by 2040. The company's stock was trading at EUR 1,016.60 in weekend trading, slightly below its last Xetra close. This initiative builds on Lilly's prior "Lilly 30x30" global health program, which exceeded its goal of reaching 30 million people annually by 2030, by providing access to healthcare for 40 million people in 2025.
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
This article compares two healthcare giants, Novo Nordisk and Pfizer, to determine which is a better investment in 2026. It analyzes their financials, risk profiles, and valuations, concluding that Pfizer, despite not being a high-growth stock, presents a better buy due to its current valuation and improving net income.
PFIZER INC (PFE-USD.SW) interactive stock chart – Yahoo Finance
This Yahoo Finance page provides an interactive stock chart for PFIZER INC (PFE-USD.SW), displaying its current stock price and performance. It also aggregates recent news articles related to Pfizer, highlighting its drug developments, stock performance, and legal matters. The page serves as a hub for investors to quickly access financial data and news regarding Pfizer.
RTX Corporation (RTX) Stock forecasts
Morningstar analysts are optimistic about RTX Corporation's prospects, highlighting the strength of its Collins Aerospace, Pratt & Whitney, and Raytheon franchises. The company is an aerospace and defense manufacturer with balanced exposure across its three core segments, primarily serving commercial aerospace and defense markets. This report offers an overview of RTX's current market position and fair value assessment.
SDGR Stock: Schrödinger Hopes Its AI Agent Can Transform Drug Discovery
Schrödinger (SDGR) leverages its physics-based software platform, molecular simulation, machine learning, and AI to transform drug discovery and materials science. The company's recent Q2 2026 results highlighted a strategic shift towards hosted software, the launch of its agentic AI product Bunsen, and significant drug discovery revenue driven by a milestone from Eli Lilly's acquisition of Ajax Therapeutics. Bunsen, designed as an AI co-scientist, is expected to be a major growth driver, with a strategic agreement already signed with Bristol Myers Squibb.
Eli Lilly and Co. stock after-hours at EUR 1,018.00: minus 0.58 percent versus prior close
Eli Lilly and Co. stock traded after-hours at EUR 1,018.00, down 0.58 percent against its prior close. The company also announced new Foundayo study findings, with the 17.2 mg dose showing significant reductions in type 2 diabetes and cardiovascular disease risks. Additionally, Foundayo demonstrated non-inferior major adverse cardiovascular event risk compared to insulin glargine in the ACHIEVE-4 trial.
Foghorn Therapeutics (FHTX) Shares Slide After Eli Lilly Collabo
Foghorn Therapeutics (FHTX) stock declined following Eli Lilly's termination of their collaboration, leading to layoffs and a shift to a preclinical pipeline. Analysts have downgraded the stock, and its Price-to-Sales ratio is significantly below historical averages, reflecting market skepticism. The company, which is unprofitable and cash-flow-negative, holds a GF Score of 67, indicating moderate growth potential but weak financial strength and profitability.
Lilly reports Foundayo data. Eli Lilly and Company stock costs EUR 1,021.90 ahead of results
Eli Lilly's oral GLP-1 medicine, Foundayo, demonstrated a 57.00% reduction in predicted 10-year type 2 diabetes risk and an 18.00% reduction in predicted cardiovascular disease risk after 72 weeks at a 17.2 mg dose. These findings, from post-hoc analyses of the ATTAIN-1 Phase 3 study, provide new data points for the company's oral obesity-medicine strategy. Investors are anticipating the third-quarter 2026 earnings call on October 29, 2026, to assess the continued growth of the company's revenue and the commercial adoption of its GLP-1 products.
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
Ohio Representative David Taylor recently purchased Amgen (NASDAQ: AMGN) stock valued between $3,003 and $45,000, with the transaction occurring on September 22, 2026. This adds to his extensive trading activity over the past three years, totaling over $357 thousand, and includes trades in companies like Microsoft and Home Depot. The article highlights the importance of congressional transaction disclosures under the STOCK Act, which aims to prevent insider trading by elected officials.
Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal
Foghorn Therapeutics announced layoffs of 40% of its workforce after Eli Lilly ended their cancer drug development partnership. The decision came after the companies decided not to advance their lead cancer drug candidate, FHD-909, and discontinued another collaborative program. This strategic shift will allow Foghorn to redirect resources to its proprietary pipeline programs and extend its cash runway.
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
Foghorn Therapeutics and Eli Lilly have discontinued the development of their SMARCA2 degrader Fhd-909 after Phase I data showed insufficient efficacy, despite acceptable tolerability. This decision will also end their broader SMARCA2 degrader program and has led to a significant restructuring at Foghorn, including a 40% workforce reduction, to prioritize other proprietary pipeline programs. The move reflects an industry trend of cutting less promising programs earlier to manage pipeline risk and optimize resource allocation.
Guggenheim cuts Foghorn Therapeutics price target on drug setback
Guggenheim lowered its price target for Foghorn Therapeutics (NASDAQ: FHTX) from $12.00 to $5.00, while maintaining a Buy rating. This adjustment follows Foghorn Therapeutics' decision, along with partner Eli Lilly, to discontinue the development of their lead drug program, FHD-909, due to insufficient monotherapy efficacy in Phase 1 trials. The company will also implement a 40% workforce reduction but maintains financial flexibility with a strong current ratio and cash reserves to pursue other pipeline programs.
Katwijk approves permits for $3 billion Eli Lilly pharmaceutical plant
The municipality of Katwijk has approved permits for Eli Lilly to build a $3 billion pharmaceutical plant, which will create about 500 jobs and produce diabetes and weight-loss medicines. Despite resident concerns about environmental impact and safety, the council rejected a referendum and voted largely in favor, citing economic benefits. Eli Lilly will initially use gas turbines for power due to electricity grid limitations and still requires further permits for production and wastewater.
More jobs, opportunities: Eli Lilly executive vice president tells Voz News company will build $6.5 billion plant in Houston
Eli Lilly is investing $6.5 billion to build a new pharmaceutical plant in northeast Houston, creating approximately 600 permanent positions and 4,000 construction jobs. Edgardo Hernández, EVP of Manufacturing Operations, highlighted Houston's logistics and proximity to suppliers as key factors for its selection. The company is also partnering with San Jacinto Community College to develop a specialized workforce and provide training for local residents.
Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run
Twist Bioscience (TWST) has seen a significant 9x gain over the past three years, prompting questions about whether its current share price of around US$188 is justified by its cash flows. A new collaboration with Eli Lilly's TuneLab, integrating Twist Bioscience's antibody data services with an AI-driven discovery platform, is expected to accelerate its technology's conversion into contracted work and cash generation. Despite a current free cash outflow, the Discounted Cash Flow model suggests the stock's intrinsic value is modestly above its trading price, contingent on a future shift to positive cash generation, while some community narratives on Simply Wall St suggest the stock might be overvalued.
C4 Therapeutics Inc (CCCC-Q) Stock Price and News
This article provides stock information and recent news for C4 Therapeutics Inc. (CCCC-Q), a biopharmaceutical company focused on developing therapies for cancer and neurodegenerative conditions. The news section highlights recent reports on their cemsidomide myeloma data, analyst ratings, financial results, and collaborations with Roche.
RTX Corporation (RTX) Stock forecasts
RTX Corporation, formed from the merger of United Technologies and Raytheon, is an aerospace and defense manufacturer. Morningstar sees promising prospects for RTX's Collins Aerospace, Pratt & Whitney, and Raytheon segments. The company has roughly equal exposure across these three segments, serving commercial aerospace and the defense market.
Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow
This article analyzes Johnson & Johnson's (JNJ) valuation using a Discounted Cash Flow (DCF) model, suggesting the stock might be undervalued given its projected future cash flows. Recent clinical trial successes for drugs like TECVAYLI and TREMFYA are expected to drive growth in the pharmaceutical pipeline, supporting an intrinsic value higher than its current share price. The article also touches on varying community narratives regarding JNJ's valuation, from fairly valued to slightly overvalued, and notes recent insider selling activity.
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
This article highlights seven biotechnology companies (ImmunityBio, Pacific Biosciences, IGC Pharma, VivoSim Labs, PDS Biotechnology, Connect Biopharma, and AEON Biopharma) that are on a 2026 watchlist due to their significant advancements in areas like cancer immunotherapy, advanced DNA sequencing, Alzheimer's research, and predictive human tissue testing. Each company has recent milestones, such as clinical trial results, FDA interactions, or strategic appointments, that make them noteworthy for investors in the final quarter of the year.
Fortive (FTV.US) Stock Price, Quote & News
This article provides a detailed overview of Fortive (FTV.US) stock, including its current price, key financial metrics, and recent news. It also presents analyst ratings and a price forecast for the company.
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts
Halozyme Therapeutics Inc. (HALO) has received a revised stock forecast from Argus, which lowered its target price to $123.00. The biotechnology company, focused on oncology therapies, is currently trading at $109.86. The report from September 30, 2026, is part of a quantitative analysis available to premium subscribers.
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
This article compares Johnson & Johnson (JNJ) and Eli Lilly (LLY) as investment options for 2026, highlighting their different approaches to the pharmaceutical market. JNJ offers diversified stability through drugs and medical devices, while LLY provides rapid growth driven by blockbuster treatments for diabetes and obesity. The analysis delves into each company's financial performance, risk profiles, and valuation metrics, concluding that Eli Lilly's high growth potential, despite its premium valuation, makes it a more compelling choice for long-term investors.
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Eli Lilly and Company announced detailed results from the Phase 3 ACHIEVE-4 trial for Foundayo (orforglipron), an oral GLP-1, in adults with type 2 diabetes and obesity or overweight. The study demonstrated cardiovascular safety, meeting non-inferiority criteria for major adverse cardiovascular events (MACE-4) compared to insulin glargine, and showed significant reductions in A1C and body weight. Foundayo also suggested potential for broader health benefits with lower risks of cardiovascular and all-cause death in pre-planned analyses, while improving other cardiometabolic health markers.
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know
Vertex Pharmaceuticals Inc. (VRTX) saw its stock price drop by 3.21% due to macroeconomic headwinds like elevated treasury yields and investor scrutiny over its recent acquisition of Crinetics Pharmaceuticals. Technical indicators show a sell signal and an oversold condition, while fundamental analysis highlights risks such as cystic fibrosis market saturation, challenges in non-CF product launches, and rising operating expenses. Analysts have an average price target of $571.93, but revised earnings estimates suggest a cautious outlook.
Pfizer Says Eczema Drug Shows Significant Skin Clearance
Pfizer announced positive Phase 2 results for its eczema drug, tilrekimig (PF-07275315), demonstrating significant skin clearance in adults with moderate-to-severe atopic dermatitis. The trial met its primary endpoint, showing increased EASI-75 achievement across various dosing regimens compared to placebo. Tilrekimig is a trispecific antibody designed to inhibit type 2 inflammation and was well-tolerated in the study.
Foghorn Slashes 40% of Workforce After Eli Lilly Ends Cancer Drug Alliance
Foghorn Therapeutics is laying off 40% of its workforce after Eli Lilly terminated their cancer drug collaboration due to FHD-909 failing to meet efficacy expectations in Phase 1 trials. The restructuring will leave Foghorn with 65 employees and extend its cash runway into the second half of 2029, as the company now focuses on its wholly owned preclinical pipeline. This marks Foghorn's second major strategic pivot in two years, following a previous program discontinuation.
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Eli Lilly and Company announced detailed results from the Phase 3 ACHIEVE-4 trial for its oral GLP-1, Foundayo (orforglipron), demonstrating cardiovascular safety and significant improvements in A1C and weight reduction in adults with type 2 diabetes and obesity/overweight. The study showed a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3 compared to insulin glargine, along with substantial reductions in cardiovascular and all-cause death. Foundayo also improved various cardiometabolic risk factors and kidney function, reinforcing its potential as a compelling treatment option.
Eli Lilly presents Foundayo data. Eli Lilly and Company stock falls 1.18 percent
Eli Lilly presented new Foundayo data showing superior weight loss and A1C reduction compared to oral semaglutide. The company's second-quarter revenue surged by 47.70 percent to USD 22.97 billion, with earnings per share exceeding consensus estimates. Despite positive financial performance and analyst price target increases, Eli Lilly's stock saw a modest decline of 1.18 percent at Lang & Schwarz.
Pfizer Says Eczema Drug Shows Significant Skin Clearance
Pfizer announced positive Phase 2 results for its eczema drug, tilrekimig, showing significant skin clearance in adults with moderate-to-severe atopic dermatitis. The drug met its primary endpoint, with a high percentage of participants achieving EASI-75 across various dosing regimens. Tilrekimig, a potential first-in-class trispecific antibody, also demonstrated good safety and tolerability.
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
Mergers and acquisitions slowed significantly in the third quarter of 2026 compared to Q2, with just under $30 billion across 22 transactions. Despite the overall slowdown, Vertex Pharmaceuticals made one of the year's largest deals by acquiring Crinetics Pharmaceuticals for an estimated $8.8 billion, expanding into specialty endocrinology. Eli Lilly was the most active acquirer in Q3, striking two deals and bringing its year-to-date total to 11 deals worth $31.7 billion.
CVS Health Corporation (NYSE:CVS) Declares Quarterly Dividend of $0.67
CVS Health Corporation (NYSE:CVS) announced a quarterly dividend of $0.665 per share, payable on November 2nd to shareholders of record as of October 22nd. This annualizes to $2.66 with a 3.1% yield, and the dividend is well-covered by earnings with a payout ratio of 37.7%. The company recently reported strong quarterly results, exceeding revenue and EPS estimates.
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn Therapeutics announced that it and Lilly will not advance the drug candidate FHD-909 and the Selective SMARCA2 degrader program due to insufficient efficacy in clinical trials, despite favorable safety. Consequently, Foghorn is prioritizing its wholly-owned pipeline, including EP300 and CBP degraders, and an immunology and inflammation program. This strategic shift involves a 40% workforce reduction, expected to extend the company's cash runway into the second half of 2029.
There’s one pharma-linked stock most investors have never heard of. It’s on Josh Brown’s list
Josh Brown and Sean Russo highlight West Pharmaceutical Services (WST) as a key player in the pharmaceutical industry that most investors overlook. West Pharmaceutical manufactures essential components for injectable drugs, benefiting from the growth of biologics, vaccines, insulin, and GLP-1 weight loss drugs. Despite a past downturn, the company's fundamentals are recovering strongly, driven by increased demand for high-value components and effective management changes, positioning it for potential further gains.
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Unicycive Therapeutics, a clinical-stage biotechnology company, announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. Manning brings over 25 years of global biopharmaceutical experience, including leadership roles in commercialization and product launches at companies like Soleno Therapeutics and PharmaEssentia Corporation. Her expertise is expected to be invaluable as Unicycive advances its lead investigational treatment, oxylanthanum carbonate, towards potential approval and prepares for commercial-stage growth.
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn Therapeutics announced that it and Lilly will not advance the FHD-909 program or the Selective SMARCA2 degrader program due to insufficient efficacy in clinical trials. As a result, Foghorn is focusing its resources on its wholly-owned pipeline, including selective EP300 and CBP degraders, and a novel immunology and inflammation program. The company is implementing an approximately 40% workforce reduction, which is expected to extend its cash runway into the second half of 2029.
The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk
This Morning Squawk newsletter covers key financial news including the Dow Jones Industrial Average's September dip, Micron Technology's impressive revenue surge and optimistic guidance, and Google's launch of its new AI model, Gemini 4 Argon. It also touches on comments from Minneapolis Fed President Neel Kashkari regarding inflation and Eli Lilly's positive trial results for a new obesity regimen.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Bristol Myers Squibb and Eli Lilly and Co. as healthcare stock investments for 2026, highlighting their differing investment profiles. Bristol Myers Squibb is presented as a deep-value dividend payer with an established but maturing portfolio, facing patent expirations and regulatory pressures. Eli Lilly is depicted as a high-growth pharmaceutical company driven by breakthroughs in metabolic treatments like GLP-1 drugs, with strong revenue growth and a more conservative debt profile. The author ultimately recommends Eli Lilly due to its significant growth potential and innovative pipeline.
Columbia Banking System to report Q3 2026 results on October 22 with a live investor call.
Columbia Banking System will release its Q3 2026 financial results on October 22, 2026, after market close, followed by a conference call at 2:00 p.m. PT. This announcement is crucial for investors to understand the bank's performance and future outlook. The company's investor relations website will host the event's registration and replay.
